Compare Equinor ASA (EQNR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Inovio Pharmaceuticals Inc — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Equinor ASA is far larger — about 905.8× Inovio Pharmaceuticals Inc's market cap, and Equinor ASA pays a 3.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EQNR | INO | |
|---|---|---|
Market Cap | $101.62B | $112.19M |
Volume | 4,991,782 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $45.75 | $2.65 |
52-Week Low | $22.41 | $0.66 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $110.31B | $83.51M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, up 3.17% today, with a bullish technical signal and strong valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $20.0 billion in 2025 and has announced dividends and share buy-backs, reflecting financial health.
The outlook is positive with a consensus price target of $87.50, implying significant upside. Key opportunities include LNG expansion plans and cost efficiency, while risks involve volatile energy prices and execution challenges. Analyst sentiment is mixed but leans bullish, supported by strong institutional interest and strategic growth initiatives.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
